[
    {
        "id": "osp-11935",
        "type": "article-journal",
        "title": "Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty",
        "author": [
            {
                "family": "Zaloga",
                "given": "Alexandra R"
            },
            {
                "family": "Khalili",
                "given": "Ashley"
            },
            {
                "family": "Ayres",
                "given": "Brandon D"
            },
            {
                "family": "Finklea",
                "given": "Brenton D"
            },
            {
                "family": "Meghpara",
                "given": "Beeran B"
            },
            {
                "family": "Rapuano",
                "given": "Christopher J"
            },
            {
                "family": "Syed",
                "given": "Zeba A"
            }
        ],
        "URL": "https://omanscience.com/en/articles/utility-of-cenegermin-for-the-management-of-neurotrophic-keratopathy-after-penetrating-keratoplasty",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "18",
        "issue": "2",
        "page": "198-204",
        "DOI": "10.4103/ojo.ojo_311_24",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Background: The study aimed to report the outcomes of patients treated with cenegermin 0.002% for neurotrophic keratopathy (NK) following penetrating keratoplasty (PK).\n\nMaterials and methods: This retrospective case series included patients evaluated at a tertiary care hospital who completed an 8-week course of cenegermin for NK within 12 months following PK. The primary outcome measure was NK stage, while secondary outcomes included complete epithelial healing, epithelial defect size, and best-corrected visual acuity (BCVA) at baseline and four time points during and following treatment. We also evaluated disease progression.\n\nResults: Fourteen eyes of 14 patients were included and demonstrated significant improvement in NK stage at 4 weeks (1.1 ± 0.7; P = 0.006) and 8 weeks after treatment initiation (0.9 ± 0.7; P = 0.002) and 1 month (0.6 ± 0.5; P < 0.001) and 6 months after treatment completion (0.8 ± 0.9; P = 0.002) compared to baseline (1.6 ± 0.5). Complete epithelial healing was noted 1 month (42.9%; P = 0.016) and 6 months after treatment completion (38.5%; P = 0.016). Epithelial defect size improved to"
    }
]